AA
BCYC

ALPS Advisors’s Bicycle Therapeutics BCYC Stock Holding History

ALPS Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Sell
40,651
-344
-0.8% -$1.97K ﹤0.01% 1029
2025
Q4 		$290K Buy
40,995
+16,872
+70% +$124K ﹤0.01% 941
2025
Q3 		$187K Sell
24,123
-1,634
-6% -$12.3K ﹤0.01% 1009
2025
Q2 		$179K Buy
+25,757
New +$205K ﹤0.01% 1010
2022
Q4 		– Sell
-16,186
Closed -$376K – 1032
2022
Q3 		$376K Sell
16,186
-1,404
-8% -$33.4K ﹤0.01% 670
2022
Q2 		$295K Buy
+17,590
New +$371K ﹤0.01% 822

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ALPS Advisors's BCYC Position: Q1 2026 in Review

ALPS Advisors reduced its Bicycle Therapeutics (BCYC) stake by 0.84% in Q1 2026, selling an estimated $1.97K and leaving 40,651 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

ALPS Advisors first reported a position in BCYC in Q2 2022 and has held it in 6 quarters since. The position peaked at $376K in Q3 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • ALPS Advisors held 40,651 shares of Bicycle Therapeutics worth $189K as of Q1 2026.
  • ALPS Advisors sold 344 Bicycle Therapeutics shares in Q1 2026, an estimated $1.97K.
  • Bicycle Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #1029 holding.
  • ALPS Advisors first reported a position in Bicycle Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • ALPS Advisors's Bicycle Therapeutics position peaked at $376K in Q3 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.